Shilpa Pharma Lifesciences received CEP from EDQM for API, Teriflunomide

Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

This is used to treat central diabetes insipidus and bedwetting

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations

Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones

Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil

Shilpa's CDMO customer placed binding purchase order

Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs